SCHEMBL20801582

SCHEMBL20801582

O=C(CCC(=O)C1CCCCCCCCC1)NCC(=O)ON1C(=O)CC(S(=O)(=O)O)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22181107 0.98 — —
SCHEMBL20801501 0.98 — —
SCHEMBL24859936 0.98 — —
SCHEMBL20801421 0.88 — —
SCHEMBL23813737 0.83 CAMK2A (0.32) —
SCHEMBL20801579 0.83 CAMK2A (0.32) —
SCHEMBL20801584 0.81 PSMB8 (0.33) —
SCHEMBL22180988 0.81 — —
SCHEMBL20801353 0.81 — —
SCHEMBL20801357 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210284750-A1 Immunoconjugate Synthesis Method BOLT BIOTHERAPEUTICS, INC. (US) 2021-09-16 — — US disclosed
US-10675358-B2 Antibody adjuvant conjugates THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-06-09 — — US disclosed
US-20190076547-A1 ANTIBODY ADJUVANT CONJUGATES BOLT BIOTHERAPEUTICS, INC. 2019-03-14 — — US disclosed
Send feedback